Position in VTGN
as of Mar 31, 2026
· filed May 5, 2026
Position Value
$11,757
-$1,857 QoQ
Shares Held
20,628
0.0% QoQ
Ownership
0.050%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in VTGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026HighTower Advisors, LLC holds $268,759,923 across 111 Biotechnology names. VTGN ranks #109 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INBX |
Inhibrx Biosciences, Inc.
|
870,200 | $58,503,546 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
58,925 | $45,527,812 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
105,859 | $35,025,567 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
65,684 | $29,330,533 | |
| 5 | RPRX |
Royalty Pharma plc
|
292,921 | $14,051,420 | |
| 6 | AXSM |
Axsome Therapeutics, Inc.
|
56,633 | $9,572,109 | |
| 7 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
146,462 | $9,183,167 | |
| 8 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
13,914 | $7,283,561 |
All Filings in VTGN
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $11,757 | 20,628 | Shares | Sole | 2026-05-05 | |
| 2025-12-31 | $13,614 | 20,628 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $73,939 | 20,828 | Shares | Sole | 2025-11-07 | |
| 2025-06-30 | $41,656 | 20,828 | Shares | Sole | 2025-08-11 | |
| 2025-03-31 | $52,070 | 20,828 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $61,442 | 20,828 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $62,692 | 20,828 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||